BofA Securities raises Amgen stock price target to $261 on FX and script trends

Published 23/07/2025, 11:36
BofA Securities raises Amgen stock price target to $261 on FX and script trends

Investing.com - BofA Securities has raised its price target on Amgen (NASDAQ:AMGN), a $164 billion biotechnology giant with a solid financial health score of "GOOD" according to InvestingPro, to $261.00 from $252.00 while maintaining an Underperform rating on the stock.

The investment firm cited positive foreign exchange adjustments and script trends for certain key products as factors behind its revised outlook for the biotechnology company, which has demonstrated strong revenue growth of 15.6% over the last twelve months and maintains a 3.11% dividend yield.

BofA’s revenue and underlying EPS estimates for the second quarter are modestly higher, up 3% and 5% respectively, according to the research note.

For 2025 and 2026, the firm has increased its total revenue estimates by 2-3% while raising EPS projections by 2-4%, which includes expectations for higher R&D expenses in the second half of 2025.

BofA also adjusted its longer-term outlook, raising both revenue and EPS estimates for the later 2020s by 3-4% and 2-4% respectively, following modest changes across product forecasts.

In other recent news, Amgen has been the subject of several analyst updates and corporate developments. UBS raised its price target for Amgen to $326, anticipating a small earnings beat for the second quarter of 2025, driven by strong growth in products like Repatha and Evenity. Similarly, Citi increased its price target to $305, pointing to the Horizon portfolio’s 6% year-over-year growth as a positive factor. However, BMO Capital lowered its price target to $335, citing concerns over a "mixed MariTide readout" at a recent conference. Piper Sandler maintained an Overweight rating with a $328 price target, following successful clinical trial results for Amgen’s cancer drug bemarituzumab. In a related development, Dr. Jyothis George, formerly of Amgen, has been appointed as Chief Medical (TASE:BLWV) Officer at NodThera. These updates highlight Amgen’s ongoing developments and the varied perspectives of financial analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.